<DOC>
	<DOCNO>NCT00573378</DOCNO>
	<brief_summary>To investigate whether patient chronic-phase chronic myeloid leukemia ( CP-CML ) achieve complete cytogenetic response ( CCyR ) imatinib ( IM ) nilotinib ( N ) treat combination tyrosine kinase inhibitor ( TKI ) interferon-α2b ( PEG-IFN-a2b , [ IFN ] ) 2 year , subsequently therapy discontinue , maintain durable molecular response therapy . Relapse-free survival ( RFS ) rate 1 year discontinuation TKI IFN measurement objective .</brief_summary>
	<brief_title>Imatinib Nilotinib With Pegylated Interferon-α2b Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Patients must diagnosis Philadelphia chromosome positive ( Ph+ ) chronic myeloid leukemia chronic phase meet follow criterion time initial diagnosis : Cytogenetic confirmation Philadelphia chromosome variant ( 9 ; 22 ) translocation . Patients may secondary chromosomal abnormality addition Philadelphia chromosome . Peripheral blood bone marrow blast count &lt; 10 % . Peripheral blood basophil count &lt; 20 % . Platelet count ≥ 100,000 x 109/L . If peripheral blood count unavailable time original diagnosis , evidence accelerate blastphase disease prior clinical medical record , allow participate . Patients must eighteen year age old . Patients must actively receive treatment CML tyrosine kinase inhibitor , either imatinib nilotinib . Patients may receive imatinib mesylate . Patients must imatinib mesylate minimum 2 year , stable dose least one consecutive year lead enrollment . Patients may receive nilotinib ( Tasigna ) frontline therapy second line therapy reason switch imatinib nilotinib intolerance imatinib . Patients switch imatinib nilotinib concern demonstration resistance frontline imatinib . Patients must nilotinib minimum 2 year , stable least one consecutive year lead enrollment . Patients must ongoing complete hematologic response ( CHR ) TKI ( imatinib nilotinib ) , define follow : WBC ≤ 10 x 109/L . Platelet count &lt; 450,000 x 109/L . No blast promyelocytes peripheral blood . No evidence diseaserelated symptom extramedullary disease , include liver spleen . Patients must complete cytogenetic response ( CCyR ) TKI ( imatinib nilotinib ) minimum 1 year lead enrollment . Complete cytogenetic response define 0 % Ph+ cell metaphase , bone marrow and/or negative peripheral blood FISH analysis BcrAbl gene fusion , ongoing CCyR must confirm bone marrow aspirate cytogenetics and/or peripheral blood FISH BcrAbl within 4 week start treatment . Patients may negative quantitative RTPCR ( qPCR ) BCRABL time enrollment , qPCR positive , patient great 1 % bcrABl / Abl /ABL transcript , present 2 consecutive qPCR analysis , perform least 3 month apart , 6 12 month lead enrollment . Patients must ECOG performance status 02 ( Appendix 13.1 ) . All patient must inform investigational nature study standard alternative therapy . All patient must sign give write informed consent accordance institutional federal guideline . Patients prior progression CML accelerate phase blast crisis . Patients previously undergone hematopoietic stem cell transplantation . Patients previously treat interferonα . Patients absolute neutrophil count ( ANC ) &lt; 1500/mm3 and/or platelet count &lt; 100,000/mm3 . Patients serum bilirubin , SGOT [ AST ] , SGPT [ ALT ] , serum creatinine &gt; 1.5 x upper limit normal ( ULN ) . Patients INR PTT &gt; 1.5 x ULN , exception patient treatment oral anticoagulant . Patients uncontrolled medical disease diabetes mellitus , neuropsychiatric disorder , infection , angina , severe hypertension , pulmonary disease ( chronic obstructive pulmonary disease [ COPD ] hypoxemia ) , major organ malfunction ( liver , kidney ) class III IV cardiac disease define New York Heart Association Criteria . Patients ( ) pregnant , ( b ) breast feeding , ( c ) childbearing potential without negative pregnancy test prior Study Day 1 , ( ) male female childbearing potential unwilling use barrier contraceptive precaution throughout trial ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Patients history another active malignancy within last five year , require treatment chemotherapy , hormonal therapy , radiation therapy . Exceptions rule include basal cell squamous cell skin carcinoma cervical carcinoma situ . Patients history noncompliance medical regimen consider potentially unreliable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>CML</keyword>
</DOC>